Article
Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips.
Applied immunohistochemistry & molecular morphology : AIMM - 1 Apr 2015
Emelyanova Marina, Arkhipova Ksenia, Mazurenko Natalia, Chudinov Alexander, Demidova Irina, Zborovskaya Irina, Lyubchenko Lyudmila, Zasedatelev Alexander, Nasedkina Tatiana
Abstract excerpt
Targeted inhibitors of the epidermal growth factor receptor (EGFR) are used for the treatment of non-small cell lung cancer (NSCLC). Somatic mutations in the EGFR gene and key effectors of the EGFR-signaling pathway (KRAS, BRAF, PIK3CA) are associated with sensitivity to these drugs. We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.